生物製藥物流：市場佔有率分析、產業趨勢與統計、成長預測（2026-2031）

據 Mordor Intelligence 稱，2025 年生物製藥物流市場價值為 1394.1 億美元，預計到 2031 年將達到 2345.8 億美元，而 2026 年為 1520.4 億美元，預測期（2026-2031 年）複合年成長率為 9.06%。

本報告按服務（運輸、倉儲、配送等）、溫度區域（低溫運輸、非低溫運輸）、產品類型（疫苗和免疫療法、細胞和基因療法等）以及地區（北美、歐洲、亞太地區、南美、中東和非洲）進行細分。市場預測以美元計價。

全球生物製藥物流市場趨勢與洞察

高附加價值生技藥品和特殊藥品的激增正在推動對低溫運輸。

低溫運輸故障每年造成產業350億美元的損失，凸顯了健全的溫度控制在經濟上的必要性。物流業者正在利用人工智慧驅動的預測分析來預測溫度偏差風險，同時加強安全措施以應對替代品日益成長的威脅。 Frontier Scientific Solutions已在威爾明頓和香農機場周邊的自由貿易區（FTZ）基礎設施上投資15億美元，以縮短運輸時間並保護高價值生技藥品。

先進療法（mRNA、細胞和基因療法）的發展使得超低溫物流不可或缺。

mRNA和病毒載體產品需要在至少-150°C的溫度下儲存。 Cryoport和SK Phrymteco共同推出了一個專注於此類療法的綜合平台，涵蓋從生產到分銷的各個環節。雖然對可在標準冷藏環境下保存mRNA的熱穩定脂質的研究可能會減少對超低溫冷凍網路的依賴，但目前的研發管線仍嚴重依賴低溫基礎設施。 DHL收購了每年處理超過60萬件超低溫貨物的CRYOPDP，這顯示專業運輸能力正朝著產業整合的方向發展。

溫控航空貨運和液態氮/乾冰供應的產能限制導致成本波動。

新冠疫苗接種期間出現的乾冰短缺凸顯了供應鏈的脆弱性。空氣分離設備正面臨能源價格飆升的困境，而航空貨運能力也面臨來自電子商務的競爭。維也納機場的藥品處理中心已將其低溫運輸空間擴大了一倍，但領先量仍然超過了可用艙位數量，導致貨運價格飆升，運輸方式也隨之改變。

細分市場分析

2025年，運輸業務在生物製藥物流市場收入中佔比高達70.12%。這主要得益於用於最後一公里配送的公路網路以及用於時效性生技藥品的空運航線。然而，隨著客戶對標籤、配套包裝和合格運輸批准等核心運輸服務的需求日益成長，預計到2031年，附加價值服務將以10.77%的年均成長率持續成長。供應商正在倉庫中應用人工智慧技術來預測容量高峰並防止溫度偏差。 Catalent的「FastChain」平台透過將即時庫存資訊與區域倉庫連接起來，展現了向需求主導履約的轉變。生物製藥物流附加價值服務市場預計將穩步擴張，這反映了監管複雜性的增加和以患者為中心的包裝需求。儘管運輸業將保持規模，但由於溫控卡車和空運供應趨緊，它將面臨價格壓力。

在運輸領域，陸路物流仍然是跨洲際零下溫度貨物運輸的主要方式，但儘管持續運輸能力有限，空運在超低溫基因療法的運輸中發揮著至關重要的作用。隨著永續性目標的推動，生物製藥的運輸方式正朝著更穩定的方向發展，海運的佔有率也穩定成長。倉儲業務的成長與客戶對異地儲存的偏好密切相關，尤其是在歐洲，符合GMP標準的新型冷藏設施正在促進跨境分銷。

預計到2025年，低溫運輸服務將佔生物製藥物流市場的68.40%，並將成為成長最快的細分市場，複合年成長率（CAGR）將達到10.49%。冷藏（2-8 度C）運輸主要支持疫苗和胰島素的配送，而超低溫（-20 度C至-150 度C）運輸正逐漸成為mRNA和細胞/基因療法的關鍵細分市場。預計到2031年，與超低溫運輸相關的生物製藥物流市場規模將成長近一倍。營運商正在投資配備真空絕熱板、相變材料和物聯網信標的氮氣乾式運輸箱，這些信標可提供即時溫度資訊。

常溫（15–25 度C）物流網路仍承擔著傳統口服固體製劑的運輸，但隨著處方清單轉向生物製藥，其成長速度正在放緩。冷凍（0 度C至 -20 度C）仍然是特定原料藥和長期庫存的小眾市場。對永續性的需求正在加速向可重複使用運輸容器和電動冷藏集裝箱的過渡，從而形成結合綠色能源和高熱容量的混合模式。利用區塊鏈技術的先導計畫會追蹤儲存歷史，以確保合規性。

區域分析

北美地區預計到2025年將保持41.20%的生物製藥物流市場佔有率，這得益於其成熟的製藥生產基地、符合GDP認證的高密度網路以及對物聯網監控技術的早期應用。諸如UPS斥資16億美元收購Andlauer Healthcare Group等大規模資本投資項目，正在加強該地區的物流基礎設施建設，並鞏固主導地位。

亞太地區預計將以11.06%的複合年成長率成長，並預計在2031年佔據市場價值成長的大部分佔有率。中國創新企業正將載體生產轉移至新加坡和泰國以分散風險，而印度則在新版GMP法規的指導下擴大注射劑生產。新加坡新建的多租戶醫藥中心體現了該地區對高標準冷藏保管和快速跨境清關的承諾。因此，與亞洲內部貿易路線相關的生物製藥物流市場預計將進一步擴張。

歐洲憑藉嚴格的監管合規和完善的公路及鐵路冷鏈網路，保持強大的市場地位。 DHL在法蘭克福附近建設的3萬平方米碳中和擴建項目，將配備低至-70 度C的超低溫倉庫，這將進一步提升歐洲大陸管理細胞和基因治療產品線的能力。儘管持續的行業重組提升了服務質量，但阿姆斯特丹史基浦機場和布魯塞爾等主要貨運門戶的運力仍然有限。

南美、中東和非洲正在湧現新的商機。政府主導的疫苗接種運動和慢性病治療的宣傳活動，推動了對認證冷藏和陸空運輸連接的需求。然而，不穩定的電網和不完善的GDP監測系統為服務品質帶來了挑戰，並減緩了基礎設施建設的步伐。

其他好處：

• Excel格式的市場預測（ME）表
• 3個月的分析師支持

目錄

第1章：引言

• 研究假設和市場定義
• 調查範圍

第2章：調查方法

第3章執行摘要

第4章 市場狀況

• 市場概覽
• 市場促進因素
  • 高附加價值生技藥品和特種藥品市場佔有率的快速成長正在推動對低溫運輸的需求。
  • 隨著先進療法（mRNA、細胞和基因療法）的發展，超低溫物流變得不可或缺。
  • 臨床試驗的全球化和去中心化正在加速向患者直接提供治療方案。
  • 由於全球GDP/GxP合規性要求日益嚴格，外包給經過認證的第三方物流公司正變得越來越重要。
  • 電子商務和D2C（直接面對消費者）的特種藥品分銷正在推動最後一公里溫控配送的發展。
  • 新興市場生技藥品生產的擴張導致跨國低溫運輸配送增加。
• 市場限制因素
  • 溫控空運貨物和液態氮的運輸能力受限，以及乾冰的供應不足，導致成本波動。
  • 世界各國不同的法規和海關要求會導致延誤和偏離規格的風險。
  • 低溫運輸營運的高碳足跡正在推動代價高昂的永續發展投資。
  • 新興地區技術工人短缺以及基礎設施缺乏達到GDP標準，限制了其可信度。
• 價值供應鏈分析
• 產業的技術創新
• 政府法規和政策
• 波特五力模型
• 聚焦生物製藥產業
• 物流和配送成本分析
• 關於冷藏倉庫基礎設施的考量
• 低溫運輸包裝市場概覽
• 地緣政治事件對市場的影響

第5章 市場規模與成長預測

• 按服務
  • 運輸
    • 路
    • 鐵路
    • 海事/海洋
    • 航空
  • 倉儲/物流
  • 附加價值服務（貼標籤、套件組裝、QP放行）
• 按溫度範圍
  • 低溫運輸
    • 室溫（15-25 度C）
    • 冷藏（2-8 度C）
    • 冷凍（0 度C至 -20 度C）
    • 超低溫/低溫（-20 度C至 -150 度C）
  • 非低溫運輸
• 依產品類型
  • 疫苗和免疫療法
  • 細胞和基因治療
  • 原料藥和散裝生技藥品
  • 市售生物製藥
  • 其他
• 最終用戶
  • 生物製藥製造商
  • CRO（合約研究組織）和 CMO（合約受託製造廠商）
  • 醫院和臨床試驗點
  • 其他最終用戶
• 按地區
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 秘魯
    • 智利
    • 阿根廷
    • 其他南美國家
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 韓國
    • 東南亞（新加坡、馬來西亞、泰國、印尼、越南、菲律賓）
    • 其他亞太國家
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 比荷盧經濟聯盟（比利時、荷蘭、盧森堡）
    • 北歐國家（丹麥、芬蘭、冰島、挪威、瑞典）
    • 其他歐洲國家
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 奈及利亞
    • 其他中東和非洲國家

第6章 競爭情勢

• 市場集中度
• 策略趨勢
• 市佔率分析
• 公司簡介
  • Deutsche Post DHL Group（DHL Global Forwarding, DHL Life Sciences & Healthcare）
  • UPS Healthcare/Marken
  • Kuehne+Nagel PharmaChain
  • FedEx Healthcare Solutions
  • Nippon Express（NX Pharma）
  • DSV Panthera Life Sciences
  • CEVA Logistics FORPATIENTS
  • SF Express Cold-Chain
  • Kerry Logistics Pharma & Healthcare
  • Americold Logistics
  • Lineage Logistics
  • Cryoport Systems
  • Yusen Logistics Healthcare
  • GEODIS PharmaHealthcare
  • Biocair
  • Maersk Pharma Ocean & Air Services
  • World Courier
  • Aramex Healthcare
  • Hellmann Worldwide Logistics-Healthcare
  • Rhenus Logistics Pharma
  • LATAM Cargo Pharma
  • AIT Worldwide Logistics-Life Sciences

第7章 市場機會與未來展望

According to Mordor Intelligence, the bio-Pharma logistics market size was valued at USD 139.41 billion in 2025 and estimated to grow from USD 152.04 billion in 2026 to reach USD 234.58 billion by 2031, at a CAGR of 9.06% during the forecast period (2026-2031).

This report is Segmented by Service (Transportation, Warehousing, and Distribution, and More), by Temperature Range (Cold Chain, and Non-Cold Chain), by Product Type (Vaccines & Immunotherapies, Cell & Gene Therapies, and More), and Geography (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Bio-Pharma Logistics Market Trends and Insights

Surge in High-Value Biologicals & Specialty Pharma Elevating Cold-Chain Demand

Cold-chain failures cost the sector USD 35 billion annually, underscoring the financial imperative for resilient temperature management. Logistics providers deploy AI-driven predictive analytics to foresee excursion risks, while security upgrades counter rising counterfeit threats. Frontier Scientific Solutions invested USD 1.5 billion in Foreign Trade Zone infrastructure around Wilmington and Shannon airports to cut transit times and safeguard high-value biologics .

Advanced Therapies Growth (mRNA, Cell & Gene) Necessitating Ultra-Low-Temperature Logistics

mRNA and viral-vector products require storage as low as -150 °C. Cryoport and SK Pharmteco launched an integrated platform spanning manufacturing and distribution tailored to such therapies. Research into thermostable lipids that preserve mRNA at standard refrigeration may ease dependence on deep-freeze networks, yet current pipelines still rely heavily on cryogenic infrastructure. DHL's acquisition of CRYOPDP, handling more than 600,000 ultra-cold consignments annually, illustrates consolidation around specialized capacity.

Capacity Constraints in Temperature-Controlled Airfreight & LN2/Dry-Ice Supply Driving Cost Volatility

Dry-ice shortages during the COVID-19 vaccine rollout revealed a fragile supply base. Air separation units wrestle with high energy prices, while airfreight belly-hold capacity competes with e-commerce. Vienna Airport's Pharma Handling Center doubled cold-chain space, yet forward bookings still exceed slot availability, causing rate spikes and forcing mode shifts.

Other drivers and restraints analyzed in the detailed report include:

1. Globalization & Decentralization of Clinical Trials Accelerating Direct-to-Patient Shipments
2. Stringent Worldwide GDP/GxP Compliance Mandating Outsourcing to Certified 3PLs
3. Divergent Global Regulatory & Customs Requirements Causing Delays and Excursion Risk

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Transportation accounted for 70.12% of bio pharma logistics market revenue in 2025, anchored by road networks for last-mile and air corridors for time-critical biologics. Nonetheless, value-added services are forecast to grow 10.77% annually to 2031 as clients demand labeling, kitting, and qualified-person release alongside core transport. Providers leverage AI in warehouses to anticipate capacity peaks and prevent temperature deviations. Catalent's FastChain platform illustrates the shift toward demand-led fulfilment, pairing real-time inventory with regional depots. The bio pharma logistics market size for value-added services is projected to widen steadily, reflecting regulatory complexity and patient-centric packaging needs. Transportation will retain scale but face pricing pressure as supply tightens in temperature-controlled trucking and airfreight.

Within transport, road logistics remains dominant for sub-zero deliveries across continental networks, while air plays a critical role in ultra-cold gene-therapy consignments despite ongoing capacity constraints. Sea freight gains modest share as sustainability targets drive modal shifts for stable biologics. Warehousing growth tracks with clients' off-site storage preferences, particularly in Europe where new GMP-compliant cold rooms unlock cross-border distribution.

Cold chain services captured 68.40% of the bio pharma logistics market in 2025 and will expand fastest at 10.49% CAGR. Refrigerated (2-8 °C) lanes underpin vaccines and insulin flows, yet ultra-cold (-20 °C to -150 °C) emerges as the star sub-segment for mRNA and cell & gene therapies. The bio pharma logistics market size tied to ultra-cold shipments is forecast to nearly double by 2031. Providers invest in vacuum-insulated panels, phase-change materials, and nitrogen-based dry shippers with IoT beacons for live temperature feeds.

Ambient (15-25 °C) networks continue to serve traditional oral solids but grow slower as formularies tilt toward biologics. Frozen (0 °C to -20 °C) remains niche for specific APIs and long-term stockpiles. Sustainability imperatives accelerate a pivot to reusable shippers and electrified reefers, creating hybrid models pairing green power with dense thermal mass. Blockchain pilots track chain-of-custody events to assure compliance.

Complete Report Scope:

• By Service
  • Transportation
    • Road
    • Rail
    • Sea/Ocean
    • Air
  • Warehousing & Distribution
  • Value-Added Services (Labelling, Kitting, QP Release)
• By Temperature Range
  • Cold Chain
    • Ambient (15-25 °C)
    • Refrigerated (2-8 °C)
    • Frozen (0 °C to -20 °C)
    • Ultra-Cold / Cryogenic (-20 °C to -150 °C)
  • Non Cold Chain
• By Product Type
  • Vaccines & Immunotherapies
  • Cell & Gene Therapies
  • APIs & Bulk Biologics
  • Finished Dose Biologics
  • Others
• By End-user
  • Bio-Pharma Manufacturers
  • CROs (Contract Research Organizations) & CMOs (Contract Manufacturing Organizations)
  • Hospitals & Clinical-Trial Sites
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Peru
    • Chile
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
    • South East Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines)
    • Rest of Asia-Pacific
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • BENELUX (Belgium, Netherlands, and Luxembourg)
    • NORDICS (Denmark, Finland, Iceland, Norway, and Sweden)
    • Rest of Europe
  • Middle East And Africa
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of Middle East And Africa

Geography Analysis

North America retained 41.20% share of the bio pharma logistics market in 2025 on the back of entrenched pharmaceutical manufacturing, dense GDP-certified networks, and the early adoption of IoT-enabled monitoring. Major capex programs, such as UPS's USD 1.6 billion acquisition of Andlauer Healthcare Group, deepen regional infrastructure and reinforce standards leadership.

Asia-Pacific is projected to grow at 11.06% CAGR and will account for the majority of the incremental market value through 2031. Chinese innovators are relocating vector production to Singapore and Thailand to diversify risk, while India expands injectables output under revised GMP rules. Singapore's new multi-tenant pharma hub embodies the region's push for high-grade cold storage and cross-border rapid clearance. As a result, the bio-pharma logistics market size related to intra-Asia trade lanes is set to accelerate.

Europe remains a powerhouse, leveraging tight regulatory compliance and extensive road-rail cold corridors. DHL's 30,000 m2 climate-neutral expansion near Frankfurt supports sub-zero warehousing down to -70 °C, reinforcing the continent's capability to manage cell & gene therapy pipelines. Ongoing consolidation raises service quality, though capacity constraints persist at key cargo gateways like Schiphol and Brussels.

South America and the Middle East & Africa exhibit emerging opportunity profiles. Government vaccine campaigns and growing chronic-disease treatment uptake catalyze the need for certified cold rooms and road-to-air interfaces. However, patchy power grids and limited GDP oversight pose service-quality challenges, slowing the pace of infrastructure upgrades.

1. Deutsche Post DHL Group (DHL Global Forwarding, DHL Life Sciences & Healthcare)
2. UPS Healthcare / Marken
3. Kuehne + Nagel PharmaChain
4. FedEx Healthcare Solutions
5. Nippon Express (NX Pharma)
6. DSV Panthera Life Sciences
7. CEVA Logistics FORPATIENTS
8. SF Express Cold-Chain
9. Kerry Logistics Pharma & Healthcare
10. Americold Logistics
11. Lineage Logistics
12. Cryoport Systems
13. Yusen Logistics Healthcare
14. GEODIS PharmaHealthcare
15. Biocair
16. Maersk Pharma Ocean & Air Services
17. World Courier
18. Aramex Healthcare
19. Hellmann Worldwide Logistics - Healthcare
20. Rhenus Logistics Pharma
21. LATAM Cargo Pharma
22. AIT Worldwide Logistics - Life Sciences

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Surge in High-Value Biologicals & Specialty Pharma Share Elevating Cold-Chain Demand
  • 4.2.2 Advanced Therapies Growth (mRNA, Cell & Gene) Necessitating Ultra-Low-Temperature Logistics
  • 4.2.3 Globalization & Decentralization of Clinical Trials Accelerating Direct-to-Patient Shipments
  • 4.2.4 Stringent Worldwide GDP/GxP Compliance Mandating Outsourcing to Certified 3PLs
  • 4.2.5 E-commerce & D2C Distribution of Specialty Medicines Boosting Last-Mile Temperature-Controlled Delivery
  • 4.2.6 Emerging-Market Biologics Manufacturing Expansion Increasing Cross-Border Cold-Chain Flows
• 4.3 Market Restraints
  • 4.3.1 Capacity Constraints in Temperature-Controlled Airfreight & LN?/Dry-Ice Supply Driving Cost Volatility
  • 4.3.2 Divergent Global Regulatory & Customs Requirements Causing Delays and Excursion Risk
  • 4.3.3 High Carbon Footprint of Cold-Chain Operations Prompting Costly Sustainability Investments
  • 4.3.4 Scarcity of Skilled Workforce & GDP-Certified Infrastructure in Emerging Regions Limiting Reliability
• 4.4 Value / Supply-Chain Analysis
• 4.5 Technological Innovations in the Industry
• 4.6 Government Regulations and Policies
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry
• 4.8 Spotlight on the Bio-Pharmaceutical Industry
• 4.9 Logistics & Distribution Cost Analysis
• 4.10 Refrigerated Warehouse Infrastructure Insights
• 4.11 Cold-Chain Packaging Market Brief
• 4.12 Impact of Geopolitical Events on the Market

5 Market Size & Growth Forecasts (Value & Volume)

• 5.1 By Service
  • 5.1.1 Transportation
    • 5.1.1.1 Road
    • 5.1.1.2 Rail
    • 5.1.1.3 Sea/Ocean
    • 5.1.1.4 Air
  • 5.1.2 Warehousing & Distribution
  • 5.1.3 Value-Added Services (Labelling, Kitting, QP Release)
• 5.2 By Temperature Range
  • 5.2.1 Cold Chain
    • 5.2.1.1 Ambient (15-25 °C)
    • 5.2.1.2 Refrigerated (2-8 °C)
    • 5.2.1.3 Frozen (0 °C to -20 °C)
    • 5.2.1.4 Ultra-Cold / Cryogenic (-20 °C to -150 °C)
  • 5.2.2 Non Cold Chain
• 5.3 By Product Type
  • 5.3.1 Vaccines & Immunotherapies
  • 5.3.2 Cell & Gene Therapies
  • 5.3.3 APIs & Bulk Biologics
  • 5.3.4 Finished Dose Biologics
  • 5.3.5 Others
• 5.4 By End-user
  • 5.4.1 Bio-Pharma Manufacturers
  • 5.4.2 CROs (Contract Research Organizations) & CMOs (Contract Manufacturing Organizations)
  • 5.4.3 Hospitals & Clinical-Trial Sites
  • 5.4.4 Other End Users
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 South America
    • 5.5.2.1 Brazil
    • 5.5.2.2 Peru
    • 5.5.2.3 Chile
    • 5.5.2.4 Argentina
    • 5.5.2.5 Rest of South America
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 India
    • 5.5.3.2 China
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 South East Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines)
    • 5.5.3.7 Rest of Asia-Pacific
  • 5.5.4 Europe
    • 5.5.4.1 United Kingdom
    • 5.5.4.2 Germany
    • 5.5.4.3 France
    • 5.5.4.4 Spain
    • 5.5.4.5 Italy
    • 5.5.4.6 BENELUX (Belgium, Netherlands, and Luxembourg)
    • 5.5.4.7 NORDICS (Denmark, Finland, Iceland, Norway, and Sweden)
    • 5.5.4.8 Rest of Europe
  • 5.5.5 Middle East And Africa
    • 5.5.5.1 United Arab Emirates
    • 5.5.5.2 Saudi Arabia
    • 5.5.5.3 South Africa
    • 5.5.5.4 Nigeria
    • 5.5.5.5 Rest of Middle East And Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.4.1 Deutsche Post DHL Group (DHL Global Forwarding, DHL Life Sciences & Healthcare)
  • 6.4.2 UPS Healthcare / Marken
  • 6.4.3 Kuehne + Nagel PharmaChain
  • 6.4.4 FedEx Healthcare Solutions
  • 6.4.5 Nippon Express (NX Pharma)
  • 6.4.6 DSV Panthera Life Sciences
  • 6.4.7 CEVA Logistics FORPATIENTS
  • 6.4.8 SF Express Cold-Chain
  • 6.4.9 Kerry Logistics Pharma & Healthcare
  • 6.4.10 Americold Logistics
  • 6.4.11 Lineage Logistics
  • 6.4.12 Cryoport Systems
  • 6.4.13 Yusen Logistics Healthcare
  • 6.4.14 GEODIS PharmaHealthcare
  • 6.4.15 Biocair
  • 6.4.16 Maersk Pharma Ocean & Air Services
  • 6.4.17 World Courier
  • 6.4.18 Aramex Healthcare
  • 6.4.19 Hellmann Worldwide Logistics - Healthcare
  • 6.4.20 Rhenus Logistics Pharma
  • 6.4.21 LATAM Cargo Pharma
  • 6.4.22 AIT Worldwide Logistics - Life Sciences

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment